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Background: Autosomal recessive polycystic kidney disease (ARPKD) is a rare but frequently severe disorder that is
typically characterized by cystic kidneys and congenital hepatic fibrosis but displays pronounced phenotypic
heterogeneity. ARPKD is among the most important causes for pediatric end stage renal disease and a leading
reason for liver-, kidney- or combined liver kidney transplantation in childhood. The underlying pathophysiology,
the mechanisms resulting in the observed clinical heterogeneity and the long-term clinical evolution of patients
remain poorly understood. Current treatment approaches continue to be largely symptomatic and opinion-based
even in most-advanced medical centers. While large clinical trials for the frequent and mostly adult onset autosomal
dominant polycystic kidney diseases have recently been conducted, therapeutic initiatives for ARPKD are facing the
challenge of small and clinically variable cohorts for which reliable end points are hard to establish.
Methods/Design: ARegPKD is an international, mostly European, observational study to deeply phenotype ARPKD
patients in a pro- and retrospective fashion. This registry study is conducted with the support of the German Society
for Pediatric Nephrology (GPN) and the European Study Consortium for Chronic Kidney Disorders Affecting Pediatric
Patients (ESCAPE Network). ARegPKD clinically characterizes long-term ARPKD courses by a web-based approach
that uses detailed basic data questionnaires in combination with yearly follow-up visits. Clinical data collection is
accompanied by associated biobanking and reference histology, thus setting roots for future translational research.
Discussion: The novel registry study ARegPKD aims to characterize miscellaneous subcohorts and to compare the
applied treatment options in a large cohort of deeply characterized patients. ARegPKD will thus provide evidence
base for clinical treatment decisions and contribute to the pathophysiological understanding of this severe
inherited disorder.
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Autosomal recessive polycystic kidney disease (ARPKD)
is a rare, but severe form of polycystic kidney disease
with unexplained phenotypic variability and a consider-
able impact on affected patients and families as well as
attending physicians. The disease is caused by mutations* Correspondence: max.liebau@uk-koeln.de
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(PKHD1) encoding a huge transmembrane protein of
poorly understood function called fibrocystin (4074 amino
acids) [1]. Fibrocystin localizes to primary cilia of cells,
classifying ARPKD as ciliopathy [2].
Within the last years basic science approaches have
brought tremendous progress in the understanding of
the genetic basis and pathomechanisms of ciliopathies
[2-5]. As a consequence first clinical trials on potential
treatment approaches for the common adult-onset auto-
somal dominant polycystic kidney disease (ADPKD)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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attention [6-12]. Still, these trials have not yet estab-
lished a clear-cut and safe general treatment therapy for
ADPKD.
With an estimated incidence of 1 in 20.000 live births
ARPKD is much rarer than ADPKD and lacks similar
targeted therapeutic approaches. Furthermore, initiatives
for randomized clinical trials on ARPKD are facing the
difficulty of clinically highly variable cohorts for which
reliable clinical study end points are hard to establish.
The underlying molecular mechanisms of the observed
clinical heterogeneity are currently poorly understood.
Genotype-phenotype correlations are confined to an
interrelation of two truncating mutations with a mostly
severe phenotype with peri- or neonatal demise and the
observation that most patients surviving the neonatal
period carry at least one missense mutation as milder
manifestation [13,14]. Mutations in modifier genes may
be involved as it has been described in other ciliopathies
[2]. Finally, PKHD1 is subject to a complex splicing pat-
tern, adding another level of complexity to mechanisms
controlling fibrocystin expression [15,16].
Clinically, the phenotypic spectrum of ARPKD ranges
from severely affected newborns with a persisting high
mortality of up to 30% often related to respiratory failure
in pulmonary hypoplasia [17] to mild affected adults with
predominant hepatic fibrosis.
Renal involvement in ARPKD is characterized by bilat-
eral massive enlargement of the kidneys and microcystic
kidney disease as a consequence of fusiform tubular dila-
tations usually deriving from the collecting duct. Kidney
function deteriorates over time and kidney transplant-
ation is required in up to 50% of patients within the first
two decades of life [14].
Beneath renal involvement ARPKD obligatory encom-
passes congenital hepatic fibrosis (CHF) due to ductal
plate malformation, with or without intrahepatic bile
duct dilatation. Portal hypertension, potentially resulting
in variceal bleeding, and cholangitis are leading clinical
manifestations of liver involvement. Additional clinical
manifestations include pronounced arterial hypertension,
secondary pulmonary hypertension, and hyponatremia.
For a detailed review of the broad spectrum of clinical
manifestations we refer to the recent excellent review ar-
ticles by Büscher et al. [18], Sweeney and Avner [19] and
Hartung and Guay-Woodford [15].
Therapeutic management of the various challenging clin-
ical problems is mainly based on the physician’s clinical ex-
periences and from retrospective data or expert opinions,
such as the recently published consensus recommenda-
tions on ARPKD treatment [20]. In summary, the manage-
ment of ARPKD currently remains largely opinion-based.
Regarding the description of clinical courses we can
refer to important previous studies by Guay-Woodford[17], Adeva [21] and Bergmann [14] who described
American and European cohorts. Still, as previously
pointed out, there are multiple remaining questions and
despite the mentioned expert opinion recommendations
[20], there is an urging need e.g. for evidence-based
management guidelines and clinical descriptions of long-
term follow-ups. Clinical or biochemical risk markers
have not yet been established and current treatment ap-
proaches have not been systematically reviewed. Finally,
the insights obtained from molecular studies on ciliopa-
thies have opened a new understanding of the under-
lying pathomechanisms. These insights may sharpen our
clinical view for subtle phenotypes and may help to clas-
sify defined subgroups of ARPKD patients in the future.
As nicely pointed out by the Consortium for Radiologic
Imaging Study of PKD (CRISP) in a very recent study,
classification into different subgroups in ADPKD may
have prognostic implications [22]. This may also apply
for ARPKD.
To address these open questions on ARPKD two re-
nowned clinical research consortia in pediatric nephrol-
ogy, i.e. the German Society for Pediatric Nephrology
(GPN) and the European Study Consortium for Chronic
Kidney Disorders Affecting Pediatric Patients (ESCAPE
Network) recently teamed up to start a joint initiative for
a clinical registry study exclusively devoted to ARPKD.
This registry study (ARegPKD) is now open for the inclu-
sion of patients. Here, we present the details of ARegPKD
for the first time.
Methods/Design
Study population
ARegPKD is an international, multicenter, pro- and
retrospective, observational study in both pediatric and
adult ARPKD patients. Inclusion criteria comprise the
diagnosis of ARPKD by histology, molecular assessment
or clinical evaluation according to the criteria of Zerres
et al [23]. Those criteria are a) typical findings on renal
imaging and b) one or more of the following criteria:
 Clinical/laboratory signs of hepatic fibrosis
 Hepatic pathology demonstrating ductal plate
abnormality
 Absence of renal enlargement and/or multiple
cysts in both parents
 Pathoanatomic diagnosis of ARPKD in an
affected sibling
 Family history consistent with autosomal
recessive inheritance.
Definite genetic, histological or clinical proof of other
cystic kidney disorders represents an exclusion criterion.
Patient inclusion is preceded by informed consent and
by approval of the registry study by a corresponding local
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the ethical standards laid down in the 1964 Declaration of
Helsinki.
Data handling
All data will be pseudonymously entered into a password-
restricted web-based database on a safe server of the
University of Cologne and secured by use of SSL-
connections (www.aregpkd.org). Subject identification will
only be possible at the local study site and participating
centers are exclusively able to review and modify data of
patients from the corresponding site. Transmitted data
will be stored in the central database on a central and safe
server at Cologne University Computing Facilities.
Data quality
In addition to automated entry checks using predefined
plausibility ranges, mandatory statements regarding
diagnosis criteria will minimize the risk for incomplete
or erroneous data entries as well as inclusion of falsely
diagnosed patients. Data entries will also be reviewed by
a pediatric nephrologist at random checks and during
regular interims analyses. Queries will be sent to the
local investigators in cases of implausibility or doubt. In
case of major problems with accomplishing regular local
data entries, an associated regional coordinator in charge
will provide support. Regional coordinators will be named
for a group of centers.
Statistical analysis
Statistical analysis will mainly focus on descriptive analysis
including calculation of relative and absolute frequenciesFigure 1 Study flow chart.for binary/categorical variables and for continuous vari-
ables calculation of mean, standard deviation, median,
interquartile range, minimum and maximum. Inferential
analyses will be planned based on first results of inter-
mediate analyses and predefined in detail in a statistical
analysis plan (SAP). Further longitudinal data regarding
outcomes of markers of renal and hepatic function, overall
survival and e.g. kidney size will be analyzed using appro-
priate statistical methods such as mixed modeling. In case
of missing data appropriate methods (e.g. multiple im-
putation) will be used to handle them. Furthermore the
aspect of multiple testing will be considered. Potential
sources of bias will be examined and considered in the
analyses.
Study organization and design
Data acquisition is partitioned in basic data and follow-
up visits (Figure 1).
*Basic data (Table 1)
Within the section of basic data details regarding clin-
ical symptoms at primary manifestation are documented.
Available results of genetic testing and family history
data regarding cystic kidney disease as well as potential
liver affection are included.
*Initial visit/follow-up visits (Table 1)
After completion of basic data the initial visit is cre-
ated for enrollment of clinical, radiologic, laboratory and
other findings of different organ systems (kidney, liver,
Table 1 Synopsis of data obtained in ARegPKD
Synopsis of data obtained in ARegPKD
Basic data
a Basic information with date of birth, sex, onset of symptoms and
initial visit at doctor
b Family history
c Pre- and perinatal period/infancy
d Initial diagnosis
e Genetics
Initial visit/yearly follow-up visits
a Patient’s status – baseline evaluation (e.g. body-measurements,
participation in studies, availability of biosamples)
b Renal status including symptoms, radiological findings, biopsy results
c Extrarenal status regarding liver (symptoms, radiological findings,
biopsy results) and other organs (spleen, cardiovascular system,
central nervous system, eyes, lungs, bones, blood)
d Laboratory values
e Medications with start and end date, dose
f Therapy including renal replacement therapy, surgical procedures
and other procedures
g Further developments with inclusion of user-defined comments
Ebner et al. BMC Nephrology  (2015) 16:22 Page 4 of 7spleen, cardiovascular system, lung, eye, central nervous
system, other organs). A patient’s medication is docu-
mented with dose and application duration, surgical pro-
cedures are provided with date, indication and possible
complications, and histological findings can be entered.
Individual aspects not specifically requested in the ques-
tionnaire can be added as free text. At least yearly follow-
ups with identical questionnaires provide data on the
clinical course in a pro- or retrospective manner.
Biobanking
Blood and tissue samples shall be taken at every visit
(both initial and/or follow-up visits). Initial blood sam-
ples include e.g. serum, plasma and EDTA blood. Yearly
follow-up blood samples (e.g. serum, plasma) shall be
collected if possible. Importantly, there will be no add-
itional interventions or blood takings, material for storing
will exclusively be obtained within routinely indicated
examinations. Samples will be pseudonymously sent to
Hannover Unified Biobank (HUB) the central biobank of
Hannover Medical School. At HUB the biomaterials will
be identified by a unique Lab-ID. HUB is one of the most
modern biobanks in Europe. It is characterized by a high
degree of automation and state-of-the-art biobank in-
frastructure according to standard operating procedures
with data safety concepts, pseudonymization tools, sample
identification via 2-D bar codes and integrated IT systems
that will enable high quality and safety standards. Stable
biobank structures, continuous temperature monitoring,
emergency power supply, and 7/24 sample maintenanceguarantee a high safety standard in the short- and long-
term storage of biomaterials.
The samples from Turkey will be pseudonymously
stored at Hacettepe Biobank at the Biobanking and Gen-
omics Research and Application Center of the Hacettepe
University.
Biosamples can be requested for basic research ques-
tions by written application to the ARegPKD steering
committee and must include a proven positive ethics
votum. Appropriation of biosamples will be restricted to
research on cystic kidney diseases.
Reference histology
Reference histology of biopsy samples is offered by the
Institute of Pathology of the University Hospital of
Cologne. Professor Reinhard Buettner, chair of pathology
at the University Hospital of Cologne, is an internationally
recognized expert for ARPKD. In addition to the assess-
ment of existing genetic analyses, reference histology
evaluation complementing local histological examination
can serve as an important factor to maintain highest
security and standards concerning the correct diagnosis of
ARPKD. Histologic evaluation will focus on the as-
sessment of liver and kidney but will include, if available,
samples from other organs. Histological samples will be
scanned by a Mirax (Zeiss) slide scanner and uploaded to
a central server connected to a web-based virtual histology
discussion platform. This will save and store all histo-
logical samples in a pseudonymous fashion and make
them available for discussion and inspection for all mem-
bers of ARegPKD.
Ethics aspects
The study protocol including patient information and
consent forms has been reviewed and approved by the
Ethics Commission of the Faculty of Medicine of Cologne
University. Corresponding local review boards are ap-
proached for confirmation of this approval.
Appropriate measures are used to guarantee maximal
data confidentiality. All patient-related clinical data is
pseudonymized locally. Blood samples are double-coded
and neither laboratories nor the central office are able to
identify individual patients.
Discussion
ARPKD is one of the most severe pediatric renal diseases
presenting with a substantial and poorly understood
phenotypic variability. Still, current management approa-
ches remain opinion-based [20], clinical or biochemical
markers for disease progression are missing, and long-
term courses have not yet been reviewed in large cohorts.
To promote and elaborate our understanding of
ARPKD, the GPN and the ESCAPE Network jointly
initiated an international registry study to pool data
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management approaches in European countries. This
database is supposed to serve as a basis for translational
research. Due to networking of two European consortia
ARegPKD is expected to collect one of the largest cohorts
of ARPKD patients with longitudinal data acquisition.
A prominent strength of the study will be the coverage
of the major proportion of European ARPKD patients
treated in highly specialized centers. Patients will be
characterized in a pro- and retrospective manner with
detailed questionnaires. We aim to get data for a deep
phenotypical characterization that may help to identify
specific subcohorts of ARPKD patients. Work by various
independent groups addressed the question of potential
differences in hepatic and renal disease progression in
ARPKD [14,17,24]. Our data may also become helpful to
give insights into this field.
Precise clinical characterization will be refined by
establishing a concomitant ARPKD specific biobank and
reference histology. This approach will set basis for trans-
lational and clinical research within a phenotypically
deeply-defined international cohort of patients.
As a registry study, ARegPKD will have substantial
limitations. Potential infirmities could arise from varying
data quality with respect to completeness and accuracy
of data, especially in case of retrospectively obtained
data. Investigator-dependency may be an issue for clinical
or radiologic examinations. Registered patients will fur-
thermore show variable extent of genetic testing with mul-
tiple techniques; in some patients without genetic testing
it may pose a difficulty to uncover phenotypic overlaps
(“phenocopies”) with other polycystic kidney disorders.
We will in most cases not have access to data on ARPKD-
fetuses in case of induced termination of pregnancy.
Finally, data may be missed or limited in cases of perinatal
or early neonatal mortality contributing to a selection bias
that will also be seen due to the character of the partici-
pating centers.
Factors influencing disease course like the develop-
ment of end stage renal disease (ESRD) or hepatic insuf-
ficiency have not yet been established. Current clinical
management focuses on symptomatic treatment in an
opinion-based manner. We are therefore interested in
long-term data regarding e.g. the time to ESRD and the
effect of sufficient control of arterial hypertension on the
deterioration of renal function. The frequently applied
RAAS-blockade with angiotensin converting enzyme in-
hibitors or angiotensin receptor blockers is based on
preliminary evidence from animal models [25-27] and
from the data on the positive effect of strict blood pres-
sure control on renal failure in children obtained in the
ESCAPE study [28]. Still in this study only a minor frac-
tion of patients suffered from ARPKD. The effect of dif-
ferent pharmacological antihypertensive classes on cystrespective kidney size and renal function remains to be
elucidated as well as the proof of efficacy of antihyper-
tensive therapy on slowing progression to end-stage-
renal-disease in the ARPKD-cohort. Parameters with
accelerating or slowing influence on development of
renal failure are still to be identified in the ARPKD-
cohort.
Additionally, we expect longitudinal data regarding the
impact of uni- and bilateral nephrectomy on dialysis
regimen and -efficacy, as well as data on the frequency
of potentially recovering kidney function within the first
year of life. As recently pointed out the currently avail-
able level of evidence on the effects of nephrectomy in
ARPKD children is very limited [20]. Furthermore, single-
center reports regarding outcomes of and indications for
simultaneous vs. sequential liver and kidney transplant-
ation in individuals with severe renal and hepatic pheno-
type [29-31] require analyses in a larger ARPKD cohort as
basis for decision-making.
For the common ADPKD recent international clin-
ical trials have studied the effect of different thera-
peutic approaches on total kidney volume (TKV) and
renal function (mTOR inhibitors, vasopressin V2-receptor
antagonists, somatostatin analogues, statin [6-10]). In
these trials TKV serves as a surrogate parameter for dis-
ease progression as data from the CRISP study have
shown that increased TKV is associated with worse out-
come in ADPKD [32]. Similar attempts for clinical trials
in ARPKD are missing. There is limited experimental data
on the role of mTOR activation in ARPKD [33-36]. Ani-
mal data in PCK rats regarding vasopressin V2-receptor
antagonism and its effect on reducing kidney weight and
cyst volume is more robust [37,38]. The transfer of the
data and studies regarding cyst growth in ADPKD on a
cohort of ARPKD patients seems to be obvious and sono-
graphic assessment of kidney length is used as a surrogate
of TKV in the ARegPKD questionnaires. Still, this transfer
is hampered by the fact, that TKV has not been es-
tablished as an indicator of renal function deterioration in
patients with ARPKD. Furthermore, TKV seems to be no
good marker for kidney function in ARPKD patients as
the most rapid growth of kidney volume is usually seen in
the early disease course while no continuous volume gain
is observed during progressive disease with loss of renal
function. As TKV cannot be used potential clinical trials
will therefore need to establish novel and specific clear-cut
primary end points for ARPKD. ARegPKD aims to address
this issue by detailed characterization of long term patient
courses to set roots for the establishment of clinical trials
on targeted treatment approaches.
In summary ARegPKD is a novel web-based inter-
national registry study aiming to provide evidence base
for clinical treatment decisions and contributing to the
understanding of ARPKD.
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